DUN-WEAH MAYSON: Open Payments
NPI 1083481352 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,048 in 34 payments from 9 companies in 2025. Trend: 2023 $16 · 2024 $1,477 · 2025 $1,048
Food & beverage: $1,048
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $207 |
| Vanda Pharmaceuticals Inc. | 7 | $191 |
| ABBVIE INC. | 4 | $188 |
| Janssen Pharmaceuticals, Inc | 5 | $171 |
| Otsuka America Pharmaceutical, Inc. | 5 | $102 |
| Alkermes, Inc. | 4 | $92 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Neurocrine BioSciences, Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
Products named: FANAPT, VRAYLAR, INVEGA SUSTENNA, AUSTEDO XR, ARISTADA, ABILIFY ASIMTUFII, UZEDY, COBENFY.
Industry payments across PA — which companies pay providers there.
